Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

Por Regan, M. M., O'Donnell, E. K., Kelly, W. K., Halabi, S., Berry, W., Urakami, S., Kikuno, N., Oh, W. K.
Publicado em 2010

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

Por Gibney, G. T., Aziz, S. A., Camp, R. L., Conrad, P., Schwartz, B. E., Chen, C. R., Kelly, W. K., Kluger, H. M.
Publicado em 2013

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782

Por Monk, J.P., Halabi, S., Picus, J., Hussain, A., Philips, G., Kaplan, E., Ahles, T., Gu, Lin, Vogelzang, N., Kelly, W.K., Small, E.J.
Publicado no Cancer (2011)

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

Por Armstrong, A J, Antonarakis, E S, Taplin, M -E, Kelly, W K, Beltran, H, Fizazi, K, Dahut, W L, Shore, N, Slovin, S, George, D, Carducci, M A, Corn, P, Danila, D, Dreicer, R, Heath, E, Rathkopf, D, Liu, G, Nanus, D, Stein, M, Smith, M R, Sternberg, C, Wilding, G, Nelson, P S, Halabi, S, Kantoff, P, Clarke, N W, Evans, C P, Heidenreich, A, Mottet, N, Gleave, M, Morris, M J, Scher, H I
Publicado no Ann Oncol (2018)